Peer Review Committee for Tumor Biology and Genomics (TBG)

Areas reviewed: In vivo tumor models, oncogenes and tumor suppressor genes in vivo, gene target validation, drug efficacy testing, human genetics/genomics, pharmacogenetics, pharmacogenomics, genetic risk, genotype to phenotype, gene therapy testing, and biomarker identification/development.

Jonathan Brody, PhD, Chair
Thomas Jefferson University
Philadelphia, PA

Scott A. Gerber, PhD, Vice Chair
Dartmouth College
Lebanon, NH

Ron Bose, MD, PhD
Washington University, St. Louis
St. Louis, MO

Kevin M. Brown, PhD
National Cancer Institute
Bethesda, MD

David Dawson, MD, PhD
University of California, Los Angeles
Los Angeles, CA

Dan G. Duda, PhD
Massachusetts General Hospital
Boston, MA

Michael E. Engel, MD, PhD
University of Utah
Salt Lake City, UT

Rani E. George, MD, PhD
Harvard Medical School
Boston, MA

Robert Gooze, Stakeholder
Oregon, WI

Lata Jayaraman, PhD
Seres Therapeutics
Cambridge, MA

Sandra McAllister, PhD
Brigham and Women’s Hospital
Boston, MA

Sanaz Memarzadeh, MD, PhD
University of California, Los Angeles
Los Angeles, CA

Nicholas Mitsiades, MD, PhD
Baylor College of Medicine
Houston, TX

Goutham Narla, MD, PhD
Case Western Reserve University
Cleveland, OH

Trudy G. Oliver, PhD
Huntsman Cancer Institute, University of Utah
Salt Lake City, UT

Kristy L. Richards, PhD, MD
Cornell University
Ithaca, NY 

Christopher Willey, MD, PhD
University of Alabama
Birmingham, AL